reference/396501

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/396501

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase I\|Journal Article\|Multicenter Study\|Research Support, Non-U.S. Gov't
endingPage	132
issn	0360-3016
issueIdentifier	1
pageRange	126-132
publicationName	International journal of radiation oncology, biology, physics
startingPage	126
bibliographicCitation	Rothschild S, Bucher SE, Bernier J, Aebersold DM, Zouhair A, Ries G, Lombrieser N, Lippuner T, Lütolf UM, Glanzmann C, Ciernik IF. Gefitinib in Combination With Irradiation With or Without Cisplatin in Patients With Inoperable Stage III Non–Small Cell Lung Cancer: A Phase I Trial. International Journal of Radiation OncologyBiologyPhysics. 2011 May;80(1):126–32. doi: 10.1016/j.ijrobp.2010.01.048.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2830fd4c37748449e95896cff54f370e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2fa8717c688d0c57b97893ada1e0bab8 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5c4034c2832b44eea1fda2cbb835093a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f08a11f21f3a8ecd1a54686e7ecbdbc0 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_59249ef4a09830e610a01179279672fe http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_782b5cff964c212891e286291fd929c1 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c4322c4afa6bcf04d189730fb061a171 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3fcd9381fa1ae1ee9b270ee99fafc431 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6da14cd5aef1d8cbf5023a3169a10ef2 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8b1e0ea8ff0285b9d0931d6e5bd02f32 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_15450c145070df74d1bd7390b6ceded0
date	2011-05-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://pubmed.ncbi.nlm.nih.gov/20646869 https://doi.org/10.1016/j.ijrobp.2010.01.048
isPartOf	http://rdf.ncbi.nlm.nih.gov/pubchem/journal/4036 https://portal.issn.org/resource/ISSN/0360-3016
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/
title	Gefitinib in Combination With Irradiation With or Without Cisplatin in Patients With Inoperable Stage III Non–Small Cell Lung Cancer: A Phase I Trial
discusses	http://id.nlm.nih.gov/mesh/M0018336 http://id.nlm.nih.gov/mesh/M0024707 http://id.nlm.nih.gov/mesh/M0001483 http://id.nlm.nih.gov/mesh/M0444984 http://id.nlm.nih.gov/mesh/M0004505
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D008175Q000188 http://id.nlm.nih.gov/mesh/D008175Q000532 http://id.nlm.nih.gov/mesh/D002289Q000532 http://id.nlm.nih.gov/mesh/D000970Q000009 http://id.nlm.nih.gov/mesh/D011799Q000009 http://id.nlm.nih.gov/mesh/D002289Q000188 http://id.nlm.nih.gov/mesh/D002945Q000009
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D005240 http://id.nlm.nih.gov/mesh/D004334 http://id.nlm.nih.gov/mesh/D008175Q000473 http://id.nlm.nih.gov/mesh/D008875 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D000328 http://id.nlm.nih.gov/mesh/D000970Q000008 http://id.nlm.nih.gov/mesh/D011799Q000008 http://id.nlm.nih.gov/mesh/D000971Q000627 http://id.nlm.nih.gov/mesh/D019540 http://id.nlm.nih.gov/mesh/D000971Q000009 http://id.nlm.nih.gov/mesh/D002289Q000473 http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D000077156 http://id.nlm.nih.gov/mesh/D000368 http://id.nlm.nih.gov/mesh/D002945Q000008 http://id.nlm.nih.gov/mesh/D016190Q000009 http://id.nlm.nih.gov/mesh/D016190Q000008
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5702198 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8911 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8661 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7521 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID123631 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7168 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11449

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID376229605 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID53788589 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129683629

Total number of triples: 69.